
The unmet need
An unmet medical need…
Up to 15% of asthma patients and 25% of COPD patients – are unresponsive to treatment
~50% of of long-term are discontinued in first year – inhaler compliance remains an issue
Side effects – current inhaler medications come with multiple side effects
COPD
Asthma
Characterized by airflow obstruction and airway inflammation
Characterized by episodes of airway narrowing in response to asthma triggers
Prevalence of ~16 Million in US
Prevalence of 25.1 Million in US
Addressable market of ~4 M in US
Addressable market of 2.5 M in US
133,575 deaths, 10.3 million physician office visits, 699,000 hospitalizations annually
4000 deaths, 12.8 million physician office visits, 1.8 million emergency room visits annually

Medical Challenges
Pulmonary diseases like COPD and asthma impact millions of lives globally, yet the fundamental treatment paradigm has remained largely unchanged for decades. Existing therapies focus on symptom management through inhaled medications, which often fail to address the underlying structural progression of the disease.
This clinical disconnect creates a massive unmet medical need for patients who do not respond adequately to traditional drugs. There is a critical requirement for an interventional approach that can directly target pulmonary dysfunction at the source, moving beyond palliative care toward definitive therapeutic results.
